Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.

July 2, 2019 updated by: Jiuda Zhao, Affiliated Hospital of Qinghai University

Comparing the Stage-for-Stage Prognosis of Patients With Cardia and Non-cardia Gastric Cancer After Operation.

To comparing the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this study is to compare the stage-for-stage prognosis of patients with cardia and non-cardia gastric cancer after operation.In this study, patients with cardiac and non-cardiac gastric cancer who undergo radical resection from January 2019 to December 2024 will be included. We will follow up the patient's progression, recurrence time and survival time.

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Gansu
      • Lanzhou, Gansu, China
        • Recruiting
        • The Second Hospital of Lanzhou University
        • Contact:
          • Enxi Li
          • Phone Number: 15809317472
    • Qinghai
      • Xining, Qinghai, China, 810000
        • Recruiting
        • Affiliated Hospital of Qinghai University
        • Contact:
      • Xining, Qinghai, China
        • Recruiting
        • People's Hospital of Qinghai Province
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

gastric cancer

Description

Inclusion Criteria:

  1. Histopathology or cytopathology proven cardia or non-cardia gastric cancer;
  2. Operable gastric cancer patients: primary lesions can be completely excision, no distant metastasis;
  3. Life expectancy of at least 6 months;
  4. ECOG（Eastern Cooperative Oncology Group ） score 0-1;
  5. Age: 18~80 years old;

  6. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function).

    For example: WBC（White blood cell count ）>4.0×109/L; NEU（Neutrophils）>1.5×109/L; PLT（Platelet）>100×109/L;

  7. Roughly normal cardiopulmonary function: No coronary heart disease, myocardial infarction, pulmonary heart disease, refractory hypertension;
  8. Not concomitant with other uncontrollable benign diseases before the recruitment;
  9. Voluntarily signed the informed consent.

Exclusion Criteria:

  1. Advanced gastric cancer patients with distant metastasis and inoperable ;
  2. Pregnant or lactating women;
  3. Patients who have no desire to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cardia gastric cancer
Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
Other: Cardia and Non-cardia gastric cancer
We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
Non-cardia gastric cancer
Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
Other: Cardia and Non-cardia gastric cancer
We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease Free Survival（DFS）
Time Frame: 5 years
The time from the primary operation to disease recurrence or death.
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival(OS)
Time Frame: 5 years
OS is defined as the time from the end of radical surgery to death for any reason or at the last follow-up.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Affiliated Hospital of Qinghai University

Collaborators

LanZhou University
Qinghai People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 8, 2019

Primary Completion (Anticipated)

December 31, 2023

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

March 28, 2019

First Submitted That Met QC Criteria

March 28, 2019

First Posted (Actual)

March 29, 2019

Study Record Updates

Last Update Posted (Actual)

July 5, 2019

Last Update Submitted That Met QC Criteria

July 2, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AHQU-2019001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on Cardia and Non-cardia gastric cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe